Autoloader

Werfen Receives 2022 IMV ServiceTrak Awards for Best Customer Satisfaction and Best Service in Hemostasis and Blood Gas

Retrieved on: 
Wednesday, January 4, 2023
Hemostasis, Original equipment manufacturer, GEM, CO-oximeter, ACL, NOVA, Chrysler, Strategic planning, Autoloader, Name, ACD, Blood, Catheter, Patent, Automation, Thrombosis, Agilent ChemStation, IBM Aptiva, Originality, Data management, Hospital, High-dependency unit, Health care, Accreditation, Coagulopathy, Information technology, OEM, Commercial Operating System (COS), POC, IMV, Pharmaceutical industry, Medical device, Medical imaging, Science, Autoimmunity, Werfen, Coagulation

BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.

Key Points: 
  • BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.
  • IMV ServiceTrak 2022 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • Results are based on interviews conducted with respondents in 1,716 clinical testing locations in the US, representing 2,169 instruments.
  • "It's an incredible honor to have the quality of our products and customer service, in both our Hemostasis and Acute Care Diagnostics business lines, recognized among the winners of the 2022 IMV awards," said Bill Crandell, Vice President of Commercial Operations, North America at Werfen.

New Cryo-Plasma Focused Ion Beam to Streamline Cellular Cryo-Electron Tomography Research

Retrieved on: 
Monday, August 1, 2022
Research, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, PPD, West Pharmaceutical Services explosion, Thermo Fisher Scientific, Laboratory, Protein, Autoloader, Neurodegeneration, Research, Solution, Patheon, Health, Infection, Rosalind Franklin Institute, Multimedia, Mindful Scientific Inc., Automation, Naismith, Fisher Scientific, TEM, Applied Biosystems, Technology, Â, Science, Cell biology, Workflow, Plasma, Invitrogen, Industrial gas, Microscope, Management

Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB), a new connected and automated microscope designed to advance the pace of cryo-electron tomography (cryo-ET) research.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB), a new connected and automated microscope designed to advance the pace of cryo-electron tomography (cryo-ET) research.
  • However, the process of preparing optimal samples for cryo-ET is still time-consuming and complex.
  • Our goal is to provide an end-to-end cryo-ET workflow for new and experienced users, said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher.
  • By expanding our automation capabilities to our cryo-PFIB portfolio, we can pave the way for cryo-ET to become a frontier technique for cell biology.

WERFEN ANNOUNCES WORLDWIDE COMMERCIAL RELEASE OF GEMWEB® LIVE REAL-TIME ONSCREEN VIEWER

Retrieved on: 
Monday, July 25, 2022
IBM Aptiva, Blood, Chrysler, POC, Company, Clopidogrel, Originality, GEM, Heparin, OEM, Elective surgery, Sigma, Solution, Compliance, ACD, Hemostasis, Patent, Agilent ChemStation, CO-oximeter, Data management, Name, Time, Catheter, ACL, Hospital, Health, Hemorheology, High-dependency unit, Autoloader, Efficiency, Original equipment manufacturer, Accreditation, Medical device, Medical imaging, Werfen, Autoimmunity

BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures. Comprehensive, rapid test results are viewed in real-time on one screen, designed to help guide goal-directed therapy and other critical needs—before, during and after surgery.

Key Points: 
  • BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures.
  • A digital solution, GEMweb Live coordinates care, enabling time-critical clinical decisions in the cardiovascular operating room (CVOR) by displaying consolidated results.
  • Now, GEMweb Live delivers real-time results throughout a cardiac procedure in one glance.
  • A multidisciplinary approach to patient management, GEMweb Live supports operational efficiency during time-sensitive procedures such as cardiac surgery.

WERFEN RECEIVES US FDA 510(K) CLEARANCE FOR ROTEM SIGMA THROMBOELASTOMETRY SYSTEM

Retrieved on: 
Monday, July 18, 2022
Anesthesiology, Coagulopathy, Solution, Hospital, CO-oximeter, PBM, Paola Lattus, Blood, Multimedia, Company, Efficiency, Bleeding, Health, Sigma, Patient safety, Compliance, Name, Accreditation, Decision-making, Program, Ranitidine bismuth citrate, Hemostasis, Liver transplantation, Surgeon, Originality, View, Autoloader, GEM, Original equipment manufacturer, POC, US Foods, Data management, VP, Critical, Heparin, OEM, Goal, Catheter, IBM Aptiva, High-dependency unit, Chrysler, FDA, ACL, ACD, Agilent ChemStation, Patent, Birth control, Medical device, Medical imaging, A5, Autoimmunity, Werfen

BEDFORD, Mass., July 18, 2022 /PRNewswire/ -- Werfen today announced the 510(k) clearance of the ROTEM sigma Thromboelastometry System by the US Food and Drug Administration (FDA). The ROTEM sigma delivers real-time, rapid and actionable results, now at the point of care (POC), to guide bleeding management. With clinical use throughout Europe, Australia, Asia, Latin America and Africa, the ROTEM sigma will be commercialized in the US in late 2022.

Key Points: 
  • The ROTEM sigma delivers real-time, rapid and actionable results, now at the point of care (POC), to guide bleeding management.
  • Built upon proven cup-and-pin technology, the ROTEM sigma leverages similar assays as its leading predecessor, the ROTEM delta Thromboelastometry System, used widely throughout North America and in thousands of peer-reviewed clinical studies.
  • For a clear picture of coagulopathy, the ROTEM sigma provides at-a-glance assessment of clot firmness and stability, enabling hemostasis optimization, while minimizing blood loss.
  • Additionally, GEMweb Plus 500 Custom Connectivity provides centralized access to results from any networked Werfen ACD system, including ROTEM sigma.

WERFEN AWARDED 2021 IMV SERVICETRAK AWARDS FOR BEST SYSTEM PERFORMANCE AND SERVICE

Retrieved on: 
Monday, March 28, 2022
Data management, IBM Aptiva, Research, Coagulation, Hospital, OEM, SR, Originality, Autoloader, ACD, Chrysler, View, Strategic planning, Commercial Operating System (COS), Multimedia, Thrombosis, ACL, Agilent ChemStation, Name, Health, Company, GEM, Hemostasis, Information management, Automation, Original equipment manufacturer, Coagulopathy, Patent, IMV, Medical device, Science, Autoimmunity, Werfen

BEDFORD, Mass., March 28, 2022 /PRNewswire/ --Werfen has received two IMV ServiceTrak Awards for 2021, including Best System Performance, for the third consecutive year, and Best Service in the Coagulation category, for the second consecutive year.

Key Points: 
  • BEDFORD, Mass., March 28, 2022 /PRNewswire/ --Werfen has received two IMV ServiceTrak Awards for 2021, including Best System Performance, for the third consecutive year, and Best Service in the Coagulation category, for the second consecutive year.
  • IMV ServiceTrak 2021 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • "The entire Werfen team is honored to be recognized yet again through these IMV awards.
  • To receive not only, best system performance but also best service is reflective of the mission we set out on every day, providing the best quality product, so customers can provide the best patient care" said Brian Durkin, Sr. Vice President of Commercial Operations at Werfen North America.

WERFEN RECEIVES US FDA 510(K) CLEARANCE FOR GEM® HEMOCHRON™ 100 WHOLE BLOOD HEMOSTASIS TESTING SYSTEM

Retrieved on: 
Tuesday, January 4, 2022
ACT, Cardiac catheterization, Agilent ChemStation, Society, Hypothermia, ACL, GEM, FDA, Data management, Name, Roman P, Heparin, Originality, ACD, High-dependency unit, Multimedia, Hospital, Health, Workflow, Maintenance, Time, Wi-Fi, Cardiopulmonary bypass, Anesthesiology, Artifact, Blood, Company, Society of Thoracic Surgeons, Chrysler, CO-oximeter, Cartridge, VP, IBM Aptiva, US Foods, POC, Circulatory system, Autoloader, View, OEM, Compliance, Solution, Patent, Efficiency, Original equipment manufacturer, Hemostasis, Medical device, Medical imaging, Werfen, Autoimmunity

BEDFORD, Mass., Jan. 4, 2022 /PRNewswire/ -- Werfen today announced the 510(k) clearance of the GEM Hemochron 100 whole blood hemostasis system by the US Food and Drug Administration (FDA).

Key Points: 
  • BEDFORD, Mass., Jan. 4, 2022 /PRNewswire/ -- Werfen today announced the 510(k) clearance of the GEM Hemochron 100 whole blood hemostasis system by the US Food and Drug Administration (FDA).
  • First introduced in 1983, generations of Hemochron systems represent continuous improvements in efficiency.Today, the GEM Hemochron 100 offers the highest level of speed, simplicity and connectivity in whole blood hemostasis testing.
  • For Whole Blood Hemostasis testing, the GEM Hemochron 100 system, ROTEM viscoelastic testing systems and VerifyNow platelet-reactivity testing system, inform key clinical decisions regarding transfusion, bleeding risk and anticoagulant dose adjustment during surgical and interventional procedures.
  • The ACD portfolio includes the GEM Premier 5000 system with Intelligent Quality Management 2 (iQM2), GEM Premier 3500 system with iQM, GEM Premier ChemSTAT system, GEMweb Plus Custom Connectivity, ROTEMviscoelastic testing systems, Hemochron systems, VerifyNow platelet function testing system, and Avoximeter CO-Oximeters.